APA House Call: Understanding Mentally Ill Mortality

Article

How do comorbidities influence patients' life expectancies? What is the role of public health programs?

Oleguer Plana-Ripoll, PhD

Oleguer Plana-Ripoll, PhD

The 2020 American Psychiatric Association (APA) Annual Meeting was cancelled this year, with plans made to convert the world-leading psychiatry conference into a two-part virtual session and educational platform for attendees.

In lieu of regular on-site coverage, HCPLive® will be running a series of interviews, insights, and reporting on topics that frequently headline the APA meeting—featuring familiar experts.

New results from a Denmark-based population cohort assessment shows patients diagnosed with a mental disorder have had a slight increase in overall life expectancy from 1995-2015, as the rate of external causes of death—suicide, unintentional deaths—decreased in the population.

However, the findings also showed the same patients had a greater rate of natural deaths over time, meaning health-related issues have been playing a more significant role into what is now an approximate seven-year difference of life expectancy between someone with, and someone without, a mental illness.

In an interview with HCPLive®, research letter author by Oleguer Plana-Ripoll, PhD, of the National Center for Register-Based Research at Aarhus University, discussed the prevalence of comorbid conditions in patients with common mental disorders including depression. He also talked about the limitations of the register-based assessment, but the nonetheless evidenced trends of decades-long improvement that alludes to improved public health outreach for suicide and other health risk factors among patients with mental illnesses.

Plana-Ripoll also discussed the strain of common compounding factors in mental illness severity—from stigma to substance abuse—and how such issues could not be weighed in this cohort.

Recent Videos
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
Veeral Sheth, MD: Assessment of EYP-1901 Supplemental Injection Use in Wet AMD | Image Credit: University Retina
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
© 2024 MJH Life Sciences

All rights reserved.